Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551911 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT04551911 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 171 participants.
The verdict
NCT04551911, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.
Interventions
- DRUG Placebo
- DRUG Rayaldee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04551911
The ClinicalTrials.gov registry entry for NCT04551911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04551911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04551911 about?
NCT04551911 is a clinical study titled "Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19". This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.
What is the current status of trial NCT04551911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2020-11-02. Estimated completion is 2021-10-08.
What interventions are being tested in trial NCT04551911?
The interventions under investigation include: Placebo (DRUG), Rayaldee (DRUG).
Who is sponsoring clinical trial NCT04551911?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.